Nutritional aspects of HIV-infected children receiving highly active antiretroviral therapy

AIDS

Volumn 17, Issue SUPPL. 1, 2003, Pages

  Miller, Tracie L ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Acquired immunodeficiency; Children; HAART; HIV; Nutrition

Indexed keywords

ABACAVIR; ACICLOVIR; AMPRENAVIR; ANTIDIABETIC AGENT; ANTIRETROVIRUS AGENT; AZITHROMYCIN; CD4 ANTIGEN; CIPROFLOXACIN; CLARITHROMYCIN; DIDANOSINE; EFAVIRENZ; ERYTHROMYCIN; GANCICLOVIR; GROWTH HORMONE; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; MEGESTROL ACETATE; NELFINAVIR; NEVIRAPINE; OXANDROLONE; PENTAMIDINE; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; SAQUINAVIR; STAVUDINE; SULFONAMIDE; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ANOREXIA; BLEEDING; BREAST MILK; CALORIE; CHILD; CHILD CARE; CHILD GROWTH; CHILD NUTRITION; CLINICAL FEATURE; DIARRHEA; DIET THERAPY; DIETARY INTAKE; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFECT; ENTERIC FEEDING; GASTROINTESTINAL SYMPTOM; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNOGLOBULIN BLOOD LEVEL; INSULIN RESISTANCE; JAUNDICE; LIPODYSTROPHY; LIVER DISEASE; LIVER TOXICITY; LYMPHOCYTE FUNCTION; MALABSORPTION; MALNUTRITION; MELENA; MOUTH ULCER; NAUSEA; NOSE FEEDING; NUTRITIONAL DISORDER; NUTRITIONAL SUPPORT; OBESITY; PANCREATITIS; PARENTERAL NUTRITION; PEPTIC ULCER; POVERTY; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN CALORIE MALNUTRITION; REVIEW; SIDE EFFECT; SOCIAL PSYCHOLOGY; T LYMPHOCYTE; TASTE DISORDER; VOMITING; WASTING SYNDROME; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION;

EID: 0038543052     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200304001-00016     Document Type: Review

References (96)

1. World Health Organization. Report on the Global HIV/AIDS Epidemic. Geneva: World Health Organization; 1999 [www.unaids.org].
2. Serwadda D, Mugerwa RD, Sewankambo NK, et al. Slim disease: a new disease in Uganda and its association with HTLV-III infection. Lancet. 1985, 2:849-852.
3. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994, 43:1-19.
4. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41:961-962.
5. Chandra RK, Kumari S. Nutrition and immunity: an overview. J Nutr 1994, 124(suppl 8):1433S-1435S.
6. Carey VJ, Yong FH, Frenkel LM, McKinney RE Jr. Pediatric AIDS prognosis using somatic growth velocity. AIDS 1998, 12:1361-1369.
7. Miller, TL, Awnetwant EL, Evans S, Morris VM, Vazquez IM. Gastrostomy tube supplementation for HIV-infected children. Pediatrics 1995, 96:696-702.
8. Kotler DP, Tierney AR, Wang J, Pierson RN. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 1989, 50:444-447.
9. Johann-Liang R, O'Neill L, Cervia J, Haller I, Giunta Y, Licholai T, Noel GJ. Energy balance, viral burden, insulin-like growth factor-1, interleukin-6 and growth impairment in children infected with human immunodeficiency virus. AIDS 2000, 14:683-690.
10. Arpadi SM, Cuff PA, Kotler DP, et al. Growth velocity, fat-free mass and energy intake are inversely related to viral load in HIV-infected children. J Nutr 2000, 130:2498-2502.
11. Moye J, Rich KC, Kalish LA, et al. Natural history of somatic growth in infants born to women infected by human immunodeficiency virus. J Pediatr 1996, 128:58-69.
12. Miller TL, Easley KA, Zhang W, et al. Maternal and infant factors associated with failure to thrive in children with vertically transmitted human immunodeficiency virus 1 infection: the Prospective, P2C2 Human Immunodeficiency Virus Multicenter Study. Pediatrics 2001, 108:1287-1296.
13. Miller TL, Evans SJ, Orav EJ, McIntosh K, Winter HS. Growth and body composition in children infected with the human immunodeficiency virus-1. Am J Clin Nutr 1993, 57:588-592.
14. Arpadi SM, Horlick MN, Wang J, Cuff P, Bamji M, Kotler DP. Body composition in prepubertal children with human immunodeficiency virus type 1 infection. Arch Pediatr Adolesc Med 1998, 152:688-693.
15. Saavedra JM, Henderson RA, Perman JA, Hotton N, Livingston RA, Yolken RH. Longitudinal assessment of growth in children born to mothers with human immunodeficiency virus infection. Arch Pediatr Adolesc Med 1995, 149:497-502.
16. McKinney RE, Robertson RW, and the Duke Pediatric AIDS Clinical Trials Unit. Effect of human immunodeficiency virus infection on the growth of young children. J Pediatr 1993, 123:579-582.
17. Kotler DP, Wang J, Pierson RN. Body composition studies in patients with acquired immunodeficiency syndrome. Am J Clin Nutr 1985, 42:1255-1265.
18. Mulligan K, Tai VW, Schambelan M. Cross-sectional and longitudinal evaluation of body composition in men with HIV infection. J Aquir Immune Defic Syndr 1997, 15:43-48.
19. de Martino M, Galli L, Chiarelli F, et al. Interleukin-6 release by cultured peripheral blood mononuclear cells inversely correlates with height velocity, bone age, insulin-like growth factor-1, and insulin-like growth factor binding protein-3 serum levels in children with perinatal HIV-1 infection. Clin Immunol 2000, 94:212-218.
20. Miller TL, McQuinn L, Orav, EJ. Upper gastrointestinal endoscopy as a diagnostic tool for children with human immunodeficiency virus infection. J Pediatr 1997, 130:766-773.
21. Johanson JF. To scope or not to scope: the role of endoscopy in the evaluation of AIDS-related diarrhea [editorial, comment]. Am J Gastroenterol 1996, 91:2261-2262.
22. Kotler DP, Reka S, Orenstein JM, Fox CH. Chronic idiopathic esophageal ulceration in the acquired immunodeficiency syndrome: characterization and treatment with corticosteriods. J Clin Gastroenterol 1992, 15:284-290.
23. Miller TL, Winter HS, Luginbuhl LM, Orav EJ, McIntosh KS. Pancreatitis in pediatric human immunodeficiency virus infection. J Pediatr 1992, 120:223-227.
24. Butler KM, Venson D, Henry N, et al. Pancreatitis in human immunodeficiency virus-infected children receiving dideoxyinosine. Pediatrics 1993, 91:747-751.
25. Bouche H, Housset JL, Carnot F, et al. AIDS-related cholangitis: diagnostic features and course in 15 patients. Hepatology 1993, 17:34-39.
26. Pol S, Romana CA, Rich S, et al. Microsporidia infection in patients with human immunodeficiency virus and unexplained cholangitis. N Engl J Med 1993, 328:95-99.
27. Beutler, B, Milsark IW, Cerami AL. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985, 229:869-871.
28. Langhans W. Bacterial products and the control of ingestive behavior: clinical implications. Nutrition 1996, 12:303-315
29. Rimaniol AC, Zylberberg H, Zavala F, Viard JP. Inflammatory cytokines and inhibitors in HIV infection: correlation between interleukin-1 receptor antagonist and weight loss. AIDS 1996, 10(12):1349-1356.
30. Tardieu M, Le Chenadec J, Persoz A, Meyer L, Blanche S, Mayaux MJ. HIV-1-related encephalopathy in infants compared with children and adults. French Pediatric HIV Infection Study and the SEROCO Group. Neurology 2000, 54:1089-1095.
31. Miller TL, Evans SE, Vasquez I, Orav EJ. Dietary intake is an important predictor of nutritional status in HIV-infected children. Pediatr Res 1997, 41:85A. [Abstract]
32. Henderson RA, Talusan K, Hutton N, Yolken RH, Caballero B. Resting energy expenditure and body composition in children with HIV infection. J Acquir Immune Defic Syndr 1998, 19:150-157.
33. Dworkin BM, Wormser GP, Axelrod F, et al. Dietary intake in patients with acquired immunodeficiency syndrome (AIDS), patients with AIDS-related complex, and serologically positive human immunodeficiency virus patients: correlations with nutritional status. J Parenter Enteral Nutr 1990, 14:605-609.
34. Sharkey SJ, Sharkey KA, Sutherland LR, Church DL, and GI/HIV Study Group. Nutritional status and food intake in human immunodeficiency virus infection. J Acquir Immune Defic Syndr 1992, 5:1091-1098.
35. Grunfeld C, Pang M, Shimizu L, Shigenaga JK, Jensen P, Feingold KR. Resting energy expenditure, caloric intake, and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr 1992, 55:455-460.
36. Abrams B, Duncan D, Hertz-Picciotto I. A prospective study of dietary intake and acquired immune deficiency syndrome in HIV-seropositive homosexual men. J Acquir Immune Defic Syndr 1993, 6:949-958.
37. Weber R, Ledergerber B, Zbinden R, et al. Enteric infections and diarrhea in human immunodeficiency virus-infected persons. Arch Int Med 1999, 159:1473-1480.
38. Ullrich R, Zeitz M, Heise W, Líage M, Hoffken G, Riecken EO. Small intestinal structure and function in patients infected with human immunodeficiency virus (HIV): evidence for HIV-induced enteropathy. Ann Intern Med 1989, 111:15-21.
39. Miller TL, Orav EJ, Martin SR, Cooper ER, McIntosh K, Winter HS. Malnutrition and carbohydrate malabsorption in children with vertically transmitted human immunodeficiency virus 1 infection. Gastroenterology 1991, 100(5 part 1):1296-1302.
40. Yolken RH, Hart W, Oung I, Shiff C, Greenson J, Perman JA. Gastrointestinal dysfunction and disaccharide intolerance in children infected with human immunodeficiency virus. J Pediatr 1991, 118:359-363.
41. Carroccio A, Fontana M, Spagnuolo MI, et al. Pancreatic dysfunction and its association with fat malabsorption in HIV infected children. Gut 1998, 43:558-563.
42. Salman EK, Haymond MW, Bayne E, et al. Protein and energy metabolism in prepubertal children with sickle cell anemia. Pediatr Res 1996, 40:34-40.
43. Stallings VA, Zemel BS, Davies JC, Cronk CE, Charney EB. Energy expenditure of children and adolescents with severe disabilities: a cerebral palsy model. Am J Clin Nutr 1996, 64:626-634.
44. Hankard R, Gottrand F, Turck D, Carpentier A, Romon M, Farriaux JP. Resting energy expenditure and energy substrate utilization in children with Duchenne Muscular Dystrophy. Pediatr Res 1996, 40:29-33.
45. Alfaro MP, Siegel RM, Baker RC, Heubi JE. Resting energy expenditure and body composition in pediatric HIV infection. Pediatr AIDS HIV Infect 1995, 6:276-280.
46. Johann-Liang R, O'Neill L, Cervia J, Haller I, Giunta Y, Licholai T, Noel GJ. Energy balance, viral burden, insulin-like growth factor-1, interleukin-6 and growth impairment in children infected with human immunodeficiency virus. AIDS 2000, 14:683-690.
47. Melchior JC, Raguin G, Boulier A, et al. Resting energy expenditure in human immunodeficiency virus-infected patients: comparison between patients with and without secondary infections. Am J Clin Nutr 1993, 57:614-619.
48. Grunfeld C, Pang M, Shimizu L, Shigenaga JK, Jensen P, Feingold KR. Resting energy expenditure, caloric intake, and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr 1992, 55:455-460.
49. Hommes MJT, Romijn JA, Godfried MH, et al. Increased resting energy expenditure in human immunodeficiency virus-infected men. Metabolism 1990, 39:1186-1190.
50. Missmer S, Speigelman D, Gorbach SL, Miller TL. Predictors of change in the functional status of children with human immunodeficiency virus infection. Pediatrics 2000, 106:e24.
51. Money J. The syndrome of abuse dwarfism (psychosocial dwarfism or reversible hyposomatotropism). Am J Dis Childhood 1977, 131:508-513.
52. Boulton TJ, Smith R, Single T. Psychosocial growth failure: a positive response to growth hormone and placebo. Acta Paediatr 1992, 81:322-325.
53. Anonymous. Children whose mothers are infected with HIV. Communicable Disease Report. CDR Weekly 1995, 5(24):111. [Letter]
54. Lifschitz MH, Wilson GS, Smith EO, Desmond MM. Fetal and postnatal growth of children born to narcotic-dependent women. Pediatrics 1983, 102:686-690.
55. Kakuda TN, Struble KA, Piscitelli SC, et al. Protease inhibitors for the treatment of human immunodeficiency virus infection. Am J Health-System Pharm 1998, 55:233-254.
56. Mueller BU, Sleaseman J, Nelson RP, et al. A phase I/II study of the protease inhibitor indinavir in children with HIV infection. Pediatrics 1998, 102:101-109.
57. Rutstein RM, Feingold A, Meislich D, Word B, Rudy B. Protease inhibitor therapy in children with perinatally acquired infection. AIDS 1997, 11:F107-F111.
58. Danner SA, Carr A, Leonard J, et al. Safety, pharmacokinetics and preliminary efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995, 333:1528-1533.
59. Working Group on Antiretroviral therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection, 15 April 1999 [http://www.cdc.gov].
60. NIH Draft Guidelines [www.HIVATIS.org]. www.hivatis.org/guidelines 7 June 2002
61. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998, 351:1881-1883.
62. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside-analogue (NRTI) therapy. AIDS 1999, 13:1659-1667.
63. Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Nucleoside reverse transcriptase inhibitor-associated mitochondrial toxicity as an etiology for lipodystrophy. AIDS 1999, 13:2311-2312.
64. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipogenesis. Lancet 1999, 354:1112-1115.
65. Van der Valk M, Gisolf EH, Reiss P, et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001, 15:847-855.
66. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001, 32:130-139.
67. Bartnof HS. New anti-HIV drug interactions, toxicities, and dosing options. BETA bulletin of experimental treatments for AIDS: a publication of the San Francisco AIDS foundation 1999, 12:60-63.
68. Christeff N, Melchior J, de Truchis P, et al. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. AIDS 1999, 13:2251-2260.
69. Domingo P, Matias-Guiu X, Pujol RM, et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 1999, 13:2261-2267.
70. Arpadi SM, Cuff PA, Horlick M, Kotler DP. Visceral obesity, hypertriglyceridemia and hypercortisolism in a boy with perinatally acquired HIV infection receiving protease inhibitor-containing antiviral treatment [letter]. AIDS 1999, 13:2312-2313.
71. Arpadi SM, Cuff PA, Hurlck M, Wang J, Kotler DP. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4-lymphocyte percentage at baseline and use of protease inhibitor and stavudine. J Acquir Immune Defic Syndr 2001, 27:30-34.
72. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type-1 children is associated with a sustained effect on growth. Pediatrics 2002, 109:e25.
73. Miller TL, Mawn B, Orav EJ, et al. The effect of protease inhibitors on growth and body composition in HIV-infected children. Pediatrics 2001, 107:e77.
74. Buchacz K, Cervia JS, Lindsey JC, et al. Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-1-infected children. Pediatrics 2001, 108:e72.
75. Jacquet D, Levine M, Ortega-Rodriquez E, et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000, 14:2123-2128.
76. Brambilla P, Bricalli D, Sala N, et al. Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in the absence of lipodystrophy. AIDS 2001, 15:2415-2422.
77. Melvin AJ, Lennon S, Mohan KM, Purnell JQ. Metabolic abnormalities in HIV type-1-infected children treated and not treated with protease inhibitors. AIDS Res Hum Retroviruses 2001, 10:1117-1123.
78. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV-1 lipodystrophy syndrome: a randomized controlled trial. JAMA 2000, 284:472-477.
79. Walli RK, Michl GM, Muhlbayer D, Brinkmann L, Geobel FD. Effects of troglitazone on insulin sensitivity in HIV-1-infected patients with protease inhibitor-associated diabetes mellitus. Res Exp Med 2000, 199:253-262.
80. Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 1999, 13:2099-2103.
81. Hadigan C, Meigs JB, Rabe J, et al. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001, 86:939-943.
82. Bonnet E, Ruidavets JB, Tueh J, et al. Apoprotein C-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy. J Clin Endocrinol Metab 2001, 86:296-302.
83. Roubenoff R, Weiss L, McDermott A, et al. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS 1999, 13:1373-1375.
84. Henderson RA, Saavedra JM, Perman JA, Hutton N, Livingston RA, Yolken RH. Effect of enteral tube feeding on growth of children with symptomatic human immunodeficiency virus infection. J Pediatr Gastroenterol Nutr 1994, 18:429-434.
85. Guarino A, Spagnuolo MI, Giacomet V, et al. Effects of nutritional rehabilitation on intestinal function and on CD4 cell number in HIV-infected children. J Pediatr Gastroenterol Nutr 2002, 4:366-371.
86. Shingadia D, Viani RM, Yogev R, et al. Gastrostomy tube insertion for improvement of adherence to highly active therapy in pediatric patients with human immunodeficiency virus. Pediatrics 2000, 105:e80.
87. Singer P, Rothkopf MM, Kvetan V, Kirvela O, Gaare J, Askanazi J. Risks and benefits of home parenteral nutrition in the acquired immunodeficiency syndrome. J Parenter Enteral Nutr 1991, 15:75-79.
88. Raviglione MC, Battan R, Pablos-Mendez A, Aceves-Casillas P, Mullen MP, Taranta A. Infection associated with Hickman catheters in patients with acquired immunodeficiency syndrome. Am J Med 1989, 86:780-786.
89. Tchekmedyian NS, Hickman M, Heber D. Treatment of anorexia and weight loss with Megestrol acetate in patients with cancer or acquired immunodeficiency syndrome. Semin Oncol 1991, 18(suppl 2):35-42.
90. Von Roenn JH, Murphy RL, Wegener N. Megestrol acetate for treatment of anorexia and cachexia associated with human immunodeficiency virus infection. Semin Oncol 1990, 17:13-16.
91. Von Roenn JH, Armstrong D, Kotler DP, et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994, 121:393-399.
92. Oster MH, Enders SR, Samuels SJ, et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med 1994, 121:400-408.
93. Clarick RH, Hanekom WA, Yogev R, Chadwick EG. Megestrol acetate treatment of growth failure in children infected with human immunodeficiency virus. Pediatrics 1997, 99:354-357.
94. Stockheim JA, Daaboul JJ, Yogev R, et al. Adrenal suppression in children with the human immunodeficiency virus treated with megestrol acetate. J Pediatr 1999, 134:368-370.
95. Lieberman SA, Butterfield GE, Harrison D, Hoffman AR. Anabolic effects of recombinant insulin-like growth factor-1 in cachectic patients with the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1994, 78:404-410.
96. Fox-Wheeler S, Heller L, Salata CM, et al. Evaluation of the effects of oxandrolone on malnourished HIV-positive pediatric patients. Pediatrics 1999, 104:e73.